Cinaciguat (BAY58-2667)
Sponsors
Bayer
Conditions
Acute Heart FailureCongestive Heart FailureHeart DecompensationHeart Failure
Phase 2
Placebo Controlled, Randomized, Double-blind, Multi-center Study to Investigate the Efficacy and Tolerability of BAY58-2667
TerminatedNCT00559650
Start: 2007-12-31End: 2009-03-31Updated: 2017-04-18
A Phase IIb Study to Investigate the Efficacy and Tolerability of Cinaciguat (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
TerminatedNCT01064037
Start: 2010-04-30End: 2011-03-31Updated: 2015-10-08
BAY58-2667 Dose Finding Trial Investigating Fixed Doses in Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
TerminatedNCT01065077
Start: 2010-03-31End: 2011-02-28Updated: 2015-10-08
A Phase IIb Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 µg/h, 10 µg/h) Given Intravenously to Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
TerminatedNCT01067859
Start: 2010-03-31End: 2010-11-30Updated: 2015-10-08